Nephrology

Uzm. Dr. Serap Yadigar

Doctor and researcher Kartal Dr. Lütfi Kırdar Şehir Hastanesi İstanbul
COVID-19Glomerulonephritis, MembranousCrush Syndrome
Open institution page
Suggest a correction

Is this your profile? Claim it and verify your details.

Claim profile

Person ↔ Disease

Which diseases does this doctor work on?

From source
  • COVID-19 8 publications
    Source: OpenAlex / PubMed MeSHView publications
  • Glomerulonephritis, Membranous 2 publications
  • Crush Syndrome 2 publications

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

  • SpecialtyNephrologysaglik.gov.trFrom source
  • InstitutionKartal Dr. Lütfi Kırdar Şehir Hastanesisaglik.gov.trFrom source
  • Area of workCOVID-19Extracted from 8 publications · Model version —From source
  • Publications69 publicationsOpenAlex, ORCIDFrom source
  • ORCID0000-0002-3156-4883ORCIDFrom source
  • Last synchronised5 November 2026 08:56https://lutfikirdareah.saglik.gov.tr/TR-1480114/doktorlarimiz.html#serap-yadigarsaglik.gov.tr

Scientific work

Publications on COVID-19

69 publications
Publications by year Most: 13, in 2026
  1. 2014: 2 publications
  2. 2015: 1 publication
  3. 2016: 3 publications
  4. 2017: 0 publications
  5. 2018: 0 publications
  6. 2019: 3 publications
  7. 2020: 10 publications
  8. 2021: 8 publications
  9. 2022: 8 publications
  10. 2023: 7 publications
  11. 2024: 7 publications
  12. 2025: 7 publications
  13. 2026: 13 publications

  1. Histopathological predictors of renal outcomes in idiopathic membranous nephropathy with a focus on global sclerotic glomeruli ratio

    Scientific Reports, 2026

    DOI 10.1038/s41598-026-61455-0 PMID 42706286 Open-access full textSource: OpenAlex

  2. Prognostic value of the ratio of globally sclerotic glomeruli in patients with idiopathic IgA nephropathy

    Scientific Reports, 2026

    DOI 10.1038/s41598-025-33114-3 PMID 41501143 2 citations (Europe PMC) Open-access full textSource: ORCID

  3. Finerenone Use in Heart Failure Patients with Type 2 Diabetes and Kidney Disease: An Analysis of the FINE-TURK Registry

    Cardiovascular Drugs and Therapy, 2026

    DOI 10.1007/s10557-026-07944-w PMID 42720721 1 citation (OpenAlex) Open-access full textSource: OpenAlex

  4. Sex Differences in Baseline Characteristics and Long-Term Outcomes of Primary Glomerular Diseases: Insights from the TSN-GOLD Registry

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15114017 PMID 42278877 Open-access full textSource: OpenAlex

  5. Hyperkalemia risk with finerenone in diabetic kidney disease: a real-world analysis from the FINE-TURK cohort

    Clinical Kidney Journal, 2026

    DOI 10.1093/ckj/sfag227 PMID 42592375 Open-access full textSource: OpenAlex

  6. Hyperkalemia Risk After Finerenone Initiation in Diabetic Kidney Disease with Elevated Baseline Potassium: A Multicenter Cohort Study

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15155758 PMID 42589862 Open-access full textSource: OpenAlex

  7. Early laboratory trajectories and short-term tolerability after finerenone initiationin diabetic kidney disease: the multicenter FINE-TURK study

    BMC Nephrology, 2026

    DOI 10.1186/s12882-026-05259-4 PMID 42693414 1 citation (OpenAlex) Open-access full textSource: OpenAlex

  8. ANTI-CCP AND RHEUMATOID FACTOR DO NOT PREDICT RESPONSE TO ANTI-TNF THERAPY IN RHEUMATOID ARTHRITIS

    Acta Medica Nicomedia, 2026

    DOI 10.53446/actamednicomedia.1773363 Open-access full textSource: ORCID

  9. Hyperkalemia Risk with Finerenone in Diabetic Kidney Disease: A Real-World Analysis from the FINE-TURK Cohort

    2026

    DOI 10.20944/preprints202605.0475.v1 Open-access full textSource: ORCID

  10. The Effect of Hemodialysis Treatment on Sarcopenia in Patients Newly Starting Hemodialysis

    Hemodialysis International, 2026

    DOI 10.1111/hdi.70040 PMID 41456604 1 citation (Europe PMC) Source: ORCID

View all 69 publications